Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma - Related Studies

Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma

This study is ongoing, but not recruiting participants.

Study NCT00436800. Last updated on July 7, 2008. Information provided by Sanofi-Aventis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Nasopharyngeal Neoplasms

2	More general conditions related to this trial
		Head and Neck Neoplasms
		Nasopharyngeal Diseases
		Neoplasms
		Neoplasms by Site
		Otorhinolaryngologic Diseases
		Otorhinolaryngologic Neoplasms
		Pharyngeal Diseases
		Pharyngeal Neoplasms
		Stomatognathic Diseases

3	Interventions listed in this trial
		Gemcitabine
		Oxaliplatin

4	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

5	Sponsors listed in this trial
		Sanofi-Aventis